Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
Sponsor: Eurofarma Laboratorios S.A.
Summary
A phase III study, multicenter, double-blind, double-dummy, randomized, single-dose, placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550 mg) in the acute treatment of migraine. ⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).
Official title: A Multicenter, Double-blind, Double-dummy, Randomized, Single-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
2068
Start Date
2022-12-30
Completion Date
2024-11-30
Last Updated
2026-09-22
Healthy Volunteers
No
Conditions
Interventions
Rizatriptan 10 mg + Naproxen 550mg
oral - single dose
Maxalt 10Mg Tablet
oral - single dose
Flanax 550mg
oral - single dose
Placebo oral tablet
oral - single dose
Locations (2)
Eurofarma Laboratorios S.A
São Paulo, São Paulo, Brazil
CEPIC
São Paulo, São Paulo, Brazil